Lilly’s COVID therapy hits wall as virus wanes
The use of COVID antibodies has fallen across the United States lately and, along with it, Lilly’s sales in that category.
Pharmaceutical
Articles
Medicare copays for new Alzheimer’s drug could reach $11,500
Separately, Dr. Aaron Kesselheim of Harvard University became the third member of an FDA advisory panel that opposed the drug to step down over the decision to approve it.
Lilly’s stock gets big boost from competitor’s new Alzheimer’s treatment
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.
‘Next big wave’: Radiation drugs track, kill cancer cells
Few such drugs are approved now, but the approach is predicted to become a new way to treat patients with other hard-to-reach or inoperable cancers.
Feds launch investigation of Lilly factory in New Jersey
Eli Lilly on Thursday said in a government filing that it has received a subpoena from the U.S. Justice Department for documents related to the factory and is cooperating with the investigation.
Pfizer coronavirus vaccine on pace to become world’s top-selling pharma product
Pfizer Inc. said Tuesday that it expects global sales of its coronavirus vaccine to reach $26 billion in 2021. Its success helps illustrate why Pfizer is planning to expand use of mRNA technology for other vaccines and therapies.
Curium plans $10M investment, 34 new jobs in Noblesville radiopharmaceutical facility
Curium, a nuclear medicine company with global headquarters in London and Paris and its North American headquarters in St. Louis, took over the Noblesville facility when it acquired Zevacor Molecular in March 2020.
Biden’s spin on J&J pause: Government putting safety first
Even without the Johnson & Johnson vaccine, the U.S. is still on pace to meet its vaccination goals. Perhaps more concerning is the potential blow to public confidence in all of the vaccines.
U.S. recommends ‘pause’ for J&J vaccine over clot reports
The CDC and FDA said Tuesday they were investigating clots in six women that occurred 6 to 13 days after vaccination.
FDA panel rejects Pfizer/Lilly arthritis drug tanezumab as too risky
The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine.
AstraZeneca: U.S. data shows vaccine effective for all adults
The company said its experts did not identify any safety concerns related to the vaccine, including finding no increased risk of rare blood clots identified in Europe.
Battle over where to purchase specialty drugs hits Indiana
Health care practitioners and insurers are fighting over the hefty prices hospitals charge for specialty drugs to treat patients with cancer, vision loss, low white-blood-cell count and other serious diseases.
Lilly’s Alzheimer’s drug shows modest benefit in mid-stage trial
Eli Lilly and Co. on Saturday morning presented highly anticipated details from a mid-stage study showing that its experimental drug slowed Alzheimer’s disease progression over about 18 months.
Insider alleges Lilly blocked her efforts to sound alarms about U.S. drug factory
Eli Lilly and Co. told Reuters news agency that it is working closely with the FDA to address concerns about the factory in Branchburg, New Jersey, which makes Trulicity.
J&J’s one-dose shot cleared, giving U.S. third COVID-19 vaccine
J&J initially is providing a few million doses and shipments to states could begin as early as Monday. By the end of March, J&J has said it expects to deliver 20 million doses to the U.S., and 100 million by summer.
Lilly signs deal to sell $210M worth of COVID-19 antibodies to U.S. government
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.
Drug executives: Big jump in vaccine supply coming soon
By the end of March, Pfizer and Moderna expect to have provided the U.S. government with a total of 220 million vaccine doses, up from the roughly 75 million shipped so far.
Scarcity of niche biotech ingredients hinder vaccine production
Scaling up production of formerly niche substances such as lipid nanoparticles for a global vaccine drive has been among the most complex challenges behind the effort.
Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.